Navigating Toxicities in CAR T-Cell Therapy and Bispecific Antibody Treatment: An Interdisciplinary Approach

Program Description
Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) have shown to improve response rates and progression-free survival in patients with hematologic malignancies. While CAR T-cell therapy and BsAbs have great potential in the cancer treatment landscape, both are accompanied by distinct and sometimes life-threatening toxicities. Oncology pharmacists must be familiar with strategies to mitigate these toxicities to facilitate improved outcomes in patients receiving CAR T-cell therapy and BsAbs. This program will examine the pharmacist’s role on the multidisciplinary care team in monitoring patients receiving CAR T-cell therapy and BsAbs to identify risk of toxicities, delayed effects, and potential quality of life issues. Opportunities for oncology pharmacists within the health system to implement standard operating procedures and assessment tools for the management of CAR T-cell therapy and BsAbs will also be discussed.

Target Audience: Health-system and oncology pharmacists

Type of Activity: Application
Release date: December 20, 2023
Expiration date: December 20, 2024

Time to complete activity: 1.5 hours
Fee: Free

Learner Level: Intermediate

Educational Objectives

At the completion of this activity, participants will be able to:

• Compare the mechanisms of action, clinical indications, and adverse effects associated with chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies (BsAbs) in cancer care
• Classify toxicities associated with CAR T-cell therapy and BsAbs, incorporating standard assessment tools, vital signs, and symptoms
• Apply evidence-based approaches to prevent, monitor, and manage toxicities associated with CAR T-cell therapy and BsAbs
• Identify the unique roles and responsibilities of health-system pharmacists in managing toxicities associated with CAR T-cell therapy and BsAbs as part of an interdisciplinary care team

Pharmacy Times Continuing Education^™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-23-460-H01-P. The activity is available for CE credit through December 20, 2024.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Javier Munoz, MD, MS, MBA, has the following relevant financial relationships with commercial interests to disclose:

Grant/Research Support: Bayer, Gilead/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, BeiGene.

Consultant: Pharmacyclics/AbbVie, Bayer, Gilead/Kite, BeiGene, Pfizer, Janssen, Celgene/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genentech/Roche, ADC Therapeutics, Epizyme, BeiGene, Novartis, Morphosys/Incyte, MEI, TG Therapeutics, AstraZeneca, Eli Lilly

Victoria Nachar, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Advisory board: ADC Therapeutics, Genmab

Laura J. Zitella, MS, RN, ACNP-BC, AOCN, has the following relevant financial relationships with commercial interests to disclose:

Consultant: AbbVie, BeiGene

The following contributors have no relevant financial relationships with commercial interests to disclose:

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Rose Namissa-Buszka, PharmD, BCPS, CHCP; Amy L. Morris, PharmD; Angelica Archibald; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Sara Scott, PharmD, BCOP, served as a medical reviewer and has the following relevant financial relationships with commercial interests to disclose: 2023-24 US Multiple Myeloma APP-PharmD Steering Committee: Pfizer, Inc.

An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms